About Azitra Inc
- Industry: Biotechnology
- Exchange: NYSE MKT LLC
- Country: US
- Website: https://azitrainc.com/
Frequently Asked Questions
What is the 52-week range for AZTR?
The 52-week high is $1.09 and the 52-week low is $0.1.
What is the P/E ratio for AZTR?
The P/E ratio data is currently unavailable.
What is the dividend yield for AZTR?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -284.75%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -1721.97%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.75.
Analyst Recommendation Trends
Wall Street analyst consensus for AZTR over the last few months:
Latest AZTR News
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Elutia (NASDAQ:ELUT) stock moved upwards by 17.2% to $0.94 during Thursday's after-market session. The market value of their outstanding shares is at $34.9 million. Intelligent Bio Solutions (NASDAQ:INBS)
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Evogene (NASDAQ:EVGN) shares increased by 75.0% to $0.72 during Tuesday's after-market session. The company's market cap stands at $4.5 million. AIxCrypto Hldgs (NASDAQ:AIXC) stock moved upwards by
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Stablecoin Development (AMEX:SDEV) stock increased by 121.6% to $3.48 during Tuesday's regular session. The market value of their outstanding shares is at $42.5 million. Iovance Biotherapeutics
Azitra Enters Sales Agreement With A.G.P. For Common Stock Offering; May Offer Common Stock Up To $3.50M Through A.G.P.
-SEC Filing
AZTR: Updated Valuation Reflects Cosmetic and EGFRi Rash Programs
By John Vandermosten, CFA NYSE: AZTR READ THE FULL AZTR RESEARCH REPORT Azitra, Inc. (NYSE: AZTR) reported second quarter 2026 financial and operational results on August 12 th , 2026, and provided a business update. Year to date 2026, Azitra has raised gross proceeds of approximately $10.5 million in capital that will support the launch of a new initiative in cosmetics and cosmeceuticals along
Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced that Travis Whitfill Ph.D., MPH, Azitra's Co-founder and Chief Operating Officer, will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, to be held from September 14-16, 2026, in New York City.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-04-20 | Staskey Norm | +35,524 | - | - |
| 2026-04-20 | Salva Francisco D. | +220,879 | - | - |
| 2026-04-20 | Whitfill Travis | +64,300 | - | - |
| 2026-03-18 | Salva Francisco D. | +4,064,050 | - | - |
| 2026-03-18 | Salva Francisco D. | +4,064,050 | - | - |
| 2026-03-18 | Salva Francisco D. | +500 | - | - |
| 2025-12-19 | Whitfill Travis | +23,724 | - | - |
| 2025-12-19 | Staskey Norm | +15,015 | - | - |
| 2025-12-19 | Schroer John R. | +3,003 | - | - |
| 2025-12-19 | Salva Francisco D. | +59,309 | - | - |
| 2025-12-19 | Ryan Barbara | +3,003 | - | - |